Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Sacituzumab govitecan and NKTR-214 plus nivolumab for bladder cancer

Speaking from the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Arjun Balar, MD, from NYU Langone Health Perlmutter Cancer Center, New York City, NY, discusses the promising results from the Phase I study with sacituzumab govitecan (NCT01631552), and the PIVOT-02 study (NCT02983045) looking at the novel combination of NKTR-214 with nivolumab for treating-bladder cancer resistant to checkpoint inhibitors.